Aim: Statin-associated muscle symptoms (SAMS) are a major determinant of poor treatment adherence and/or discontinuation, but a definitive diagnosis of SAMS is challenging. The PROSISA study was an observational retrospective study aimed to assess the prevalence of reported SAMS in a cohort of dyslipidaemic patients. Methods: Demographic/anamnestic data, biochemical values and occurrence of SAMS were collected by 23 Italian Lipid Clinics. Adjusted logistic regression was performed to estimate odds ratio (OR) and 95% confidence intervals for association between probability of reporting SAMS and several factors. Results: Analyses were carried out on 16 717 statin-treated patients (mean ± SD, age 60.5 ± 12.0 years; 52.1% men). During statin therapy, 9.6% (N = 1599) of patients reported SAMS. Women and physically active subjects were more likely to report SAMS (OR 1.23 [1.10–1.37] and OR 1.35 [1.14–1.60], respectively), whist age ≥ 65 (OR 0.79 [0.70–0.89]), presence of type 2 diabetes mellitus (OR 0.62 [0.51–0.74]), use of concomitant nonstatin lipid-lowering drugs (OR 0.87 [0.76–0.99]), use of high-intensity statins (OR 0.79 [0.69–0.90]) and use of potential interacting drugs (OR 0.63 [0.48–0.84]) were associated with lower probability of reporting SAMS. Amongst patients reporting SAMS, 82.2% underwent dechallenge (treatment interruption) and/or rechallenge (change or restart of statin therapy), with reappearance of muscular symptoms in 38.4% (3.01% of the whole cohort). Conclusions: The reported prevalence of SAMS was 9.6% of the whole PROSISA cohort, but only a third of patients still reported SAMS after dechallenge/rechallenge. These results emphasize the need for a better management of SAMS to implement a more accurate diagnosis and treatment re-evaluation.

Reported muscle symptoms during statin treatment amongst Italian dyslipidaemic patients in the real-life setting: the PROSISA Study / Casula, M.; Gazzotti, M.; Bonaiti, F.; Oimastroni, E.; Arca, M.; Averna, M.; Zambon, A.; Catapano, A. L.; Arca, M.; Montali, A.; Averna, M.; Giammanco, A.; Biolo, G.; Vinci, P.; Borghi, C.; D'Addato, S.; Bossi, A. C.; Meregalli, G.; Branchi, A.; Squiccimarro, G.; Cavalot, F.; Ramadori, L.; Cipollone, F.; Bucci, M.; Del Ben, M.; Angelico, F.; Fiorenza, A. M.; Colombo, E.; Grigore, L.; Zampoleri, V.; Lupattelli, G.; Gandolfo, V.; Mandraffino, G.; Savarino, F.; Mombelli, G.; Pavanello, C.; Pisciotta, L.; Pasta, A.; Purrello, F.; Scicali, R.; Rubba, P.; Fortunato, G.; Sabba, C.; Suppressa, P.; Sarzani, R.; Di Pentima, C.; Vigna, G. B.; Colangiulo, A.; Werba, J. P.; Vigo, L. M.; Zambon, S.; Previato, L.; Zenti, M. G.; Maneschi, C.. - In: JOURNAL OF INTERNAL MEDICINE. - ISSN 0954-6820. - 290:1(2021), pp. 116-128. [10.1111/joim.13219]

Reported muscle symptoms during statin treatment amongst Italian dyslipidaemic patients in the real-life setting: the PROSISA Study

Rubba P.;Fortunato G.;
2021

Abstract

Aim: Statin-associated muscle symptoms (SAMS) are a major determinant of poor treatment adherence and/or discontinuation, but a definitive diagnosis of SAMS is challenging. The PROSISA study was an observational retrospective study aimed to assess the prevalence of reported SAMS in a cohort of dyslipidaemic patients. Methods: Demographic/anamnestic data, biochemical values and occurrence of SAMS were collected by 23 Italian Lipid Clinics. Adjusted logistic regression was performed to estimate odds ratio (OR) and 95% confidence intervals for association between probability of reporting SAMS and several factors. Results: Analyses were carried out on 16 717 statin-treated patients (mean ± SD, age 60.5 ± 12.0 years; 52.1% men). During statin therapy, 9.6% (N = 1599) of patients reported SAMS. Women and physically active subjects were more likely to report SAMS (OR 1.23 [1.10–1.37] and OR 1.35 [1.14–1.60], respectively), whist age ≥ 65 (OR 0.79 [0.70–0.89]), presence of type 2 diabetes mellitus (OR 0.62 [0.51–0.74]), use of concomitant nonstatin lipid-lowering drugs (OR 0.87 [0.76–0.99]), use of high-intensity statins (OR 0.79 [0.69–0.90]) and use of potential interacting drugs (OR 0.63 [0.48–0.84]) were associated with lower probability of reporting SAMS. Amongst patients reporting SAMS, 82.2% underwent dechallenge (treatment interruption) and/or rechallenge (change or restart of statin therapy), with reappearance of muscular symptoms in 38.4% (3.01% of the whole cohort). Conclusions: The reported prevalence of SAMS was 9.6% of the whole PROSISA cohort, but only a third of patients still reported SAMS after dechallenge/rechallenge. These results emphasize the need for a better management of SAMS to implement a more accurate diagnosis and treatment re-evaluation.
2021
Reported muscle symptoms during statin treatment amongst Italian dyslipidaemic patients in the real-life setting: the PROSISA Study / Casula, M.; Gazzotti, M.; Bonaiti, F.; Oimastroni, E.; Arca, M.; Averna, M.; Zambon, A.; Catapano, A. L.; Arca, M.; Montali, A.; Averna, M.; Giammanco, A.; Biolo, G.; Vinci, P.; Borghi, C.; D'Addato, S.; Bossi, A. C.; Meregalli, G.; Branchi, A.; Squiccimarro, G.; Cavalot, F.; Ramadori, L.; Cipollone, F.; Bucci, M.; Del Ben, M.; Angelico, F.; Fiorenza, A. M.; Colombo, E.; Grigore, L.; Zampoleri, V.; Lupattelli, G.; Gandolfo, V.; Mandraffino, G.; Savarino, F.; Mombelli, G.; Pavanello, C.; Pisciotta, L.; Pasta, A.; Purrello, F.; Scicali, R.; Rubba, P.; Fortunato, G.; Sabba, C.; Suppressa, P.; Sarzani, R.; Di Pentima, C.; Vigna, G. B.; Colangiulo, A.; Werba, J. P.; Vigo, L. M.; Zambon, S.; Previato, L.; Zenti, M. G.; Maneschi, C.. - In: JOURNAL OF INTERNAL MEDICINE. - ISSN 0954-6820. - 290:1(2021), pp. 116-128. [10.1111/joim.13219]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/829533
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 18
  • ???jsp.display-item.citation.isi??? 17
social impact